Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$4.78
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.78
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.71 - $7.75
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$103.45M
Enterprise Value-$50.64B
Total Cash (Recent Filing)$50.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 18, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap-489.50
Enterprise Value/Revenue-6.38K
Enterprise Value/Gross Profit-6.39K
Enterprise Value/Ebitda2.32K
Forecast
1Y Price Target
$15.40Price Target Upside222.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$2.71M
Bulls Say, Bears Say
Bulls Say
Regulatory AdvancementsFast Track designation and IND acceptance materially improve the company’s regulatory posture. These designations foster more frequent agency interaction, can shorten review timelines, and structurally reduce regulatory tail risk, improving the odds of advancing COYA 302 toward approval over the coming months.
Conservative Balance SheetZero reported debt provides meaningful financial flexibility for a clinical-stage biotech. Conservative leverage lowers near-term solvency risk and gives management optionality on financing strategies, allowing focus on program execution and staged capital raises rather than servicing debt obligations.
Extended Clinical Data GenerationMoving patients into a blinded extension and re-randomizing placebo to active arms extends follow-up to 48 weeks, strengthening durability and safety datasets. Longer controlled exposure improves evidentiary quality for regulators and payers, reducing binary readout risk and supporting longer-term commercialization planning.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the company cannot self-finance its development trajectory. This creates ongoing reliance on equity or other external financing, increasing dilution risk and creating execution pressure if capital markets tighten or trial timelines extend.
Lack Of ProfitabilityDespite recent revenue acceleration, gross profits remain low and net losses are large and persistent. The structural absence of profitability means returns hinge on clinical success; until meaningful margin improvement occurs, the business model requires external funding and remains high risk for longer-term investors.
Limited Operational ScaleA headcount of eight indicates a very lean internal operating base to manage multi-site trials, regulatory submissions, and commercial planning. This heightens dependence on CROs, consultants and partners, which can slow execution, increase outsourcing costs, and raise single-point operational risks over the medium term.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $103.45M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 68 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.096.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,184 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went up 2.632%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.40 (222.18% Upside)
$15.40 (222.18% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
-0.17%
Trailing 12-Months
Asset Growth
38.71%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$15.40
▲(222.18% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
4.39% Mutual Funds
24.25% Other Institutional Investors
62.84% Public Companies and
Individual Investors